Promising New Therapy for Osteosarcoma

We’d like to draw your attention to a promising new therapy for osteosarcoma patients that recently went to clinical trial at the Masonic Cancer Center and at 30 other hospitals around the country. This is exciting news for a disease which has had little in the way of new treatments in the past 30 years.

Masonic Cancer Center of the University of Minnesota researchers, led by Dr. Brandon Moriarity, developed this therapy which uses an antibody, VX15, developed by Vaccinex, to block the activity if semaphorin 4D (SEMA4D), a causative gene of osteosarcoma. The VX15 activates the immune system and can cause the immune system to kill the osteosarcoma cancer cells.

Rein in Sarcoma is proud to have contributed to the funding of this research. You can read more details about this exciting development in a February Pioneer Press article.

1. Divine, M (2018), ‘A new cancer treatment is in clinical trial thanks to Zach Sobiech fund’,, 10 February, accessed March 5, 2018.